SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7371)11/22/2002 1:11:05 PM
From: Sam Citron  Read Replies (1) | Respond to of 52153
 
I would assume you are right as a precaution for multi-dose vials. I'm still trying to determine what compounds look the most promising as candidates to replace thimerosal.



To: Biomaven who wrote (7371)11/26/2002 11:44:38 AM
From: Sam Citron  Respond to of 52153
 
If your assumption is correct that preservatives may not be necessary in single-dose vials, then in an ideal world, consumers would be given a choice whether to pay a little more for a single-dose vial of a vaccine that does not contain a mercury-derived preservative. I wonder why the US health care system has not yet accommodated such basic choice, perhaps through a higher co-pay, as for non-generics.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News